Unresectable hepatocellular carcinoma: prospects for drug therapy with lenvatinib
https://doi.org/10.18027/2224-5057-2021-11-3-45-52
Abstract
There is a number of unresolved issues regarding the systemic therapy administration for hepatocellular carcinoma (HCC). Their solution is facilitated by accumulating real‑world study results. Lenvatinib therapy is a recognized drug with a good efficacy and safety profile for the treatment of HCC. Subanalyses of the REFLECT study showed that the absence of stratification by baseline AFP and baseline liver function, as well as the lack of options for subsequent drug therapy after lenvatinib, also affects the outcomes. Once these factors are taken into account, the hypothesis of superiority of lenvatinib to sorafenib and other drugs can be tested. Real‑world clinical studies have demonstrated positive results of lenvatinib therapy in patients with Child‑Pugh class B liver function, provided recommendations on the sequence of systemic therapy after lenvatinib and on the use of lenvatinib in patients with BCLC stage B, along with considering the possibility of lenvatinib monotherapy and the prospects for its use in patients with nHCC. Further real‑world studies of lenvatinib for HCC in the Russian population are required.
About the Authors
V. V. Breder
N. N. Blokhin National Medical Research Center of Oncology; Interdisciplinary Society of Liver Tumor Specialists
Russian Federation
Russian Federation
Valery V. Breder, MD, PhD, DSc, Leading Research Associate, President
Moscow
D. T. Abdurakhmanov
I. M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Dzhamal T. Abdurakhmanov, MD, PhD, DSc, Professor of the Department of Therapy and Occupational Diseases and the
Department of Human Pathology
Moscow
V. V. Petkau
Ural State Medical University
Russian Federation
Russian Federation
Vladislav V. Petkau, MD, PhD, Associate Professor of the Department of Oncology
Ekaterinburg
P. V. Balakhnin
Saint Petersburg Clinical Research and Practice Centre for Specialized Care (Oncological)
Russian Federation
Russian Federation
Pavel V. Balakhnin, MD, PhD, Head of the Department of Image‑guided Surgery
Saint Petersburg
M. V. Volkonsky
Moscow Municipal Oncological Hospital No. 62
Russian Federation
Russian Federation
Mikhail V. Volkonsky, Head of Day Hospital No. 1
Moscow
K. S. Grechukhina
Moscow Clinical Research Center named after A. S. Loginov
Russian Federation
Russian Federation
Katerina S. Grechukhina, Oncologist, Oncology Day Hospital
Moscow
M. A. Zafirova
Sverdlovsk Regional Oncological Center
Russian Federation
Russian Federation
Marina A. Zafrova, Head of Chemotherapy Service
Ekaterinburg
I. A. Mikerov
Sverdlovsk Regional Oncological Center
Russian Federation
Russian Federation
Ilya A. Mikerov, oncologist
Ekaterinburg
I. A. Pokataev
Municipal Clinical Oncological Hospital No. 1
Russian Federation
Russian Federation
Ilya A. Pokataev, Head of Chemotherapy Service
Moscow
A. I. Khasanova
Kazan (Privolzhsky) Federal University
Russian Federation
Russian Federation
Alfya I. Khasanova, MD, PhD, Head of the Oncology Department, Scientific and Clinical Center for Precision and Regenerative Medicine
Kazan
References
1. American Cancer Society. Cancer facts & figures 2020. (2020). Электронный ресурс. Режим доступа: https://www.cancer. org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf.
2. Yang, Ju Dong, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nature reviews Gastroenterology & Hepatology. 2019; 16 (10): 589-604.
3. Singal A. G. et al. Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA. Future Oncology. 2021. 17 (21) https://doi.org/10.2217/fon-2021-0242.
4. Омельяновский В. В., Максимкина Е. А., Ивахненко О. И., Авксентьева М. В., Сура М. В., Хачатрян Г. Р. Соверше нствование системы формирования перечней лекарственных препаратов для медицинского применения: анализ изменений Постановления Правительства РФ №871. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2020;13 (2):113-123. https://doi.org/10.17749/2070-4909/farmakoekonomika. 2020.032.
5. Журавлева Н. И., Шубина Л. С., Сухоруких О. A. Обзор методик оценки достоверности научных доказательств и убедительности рекомендаций, применяемых при разработке клинических рекомендаций в Российской Федерации. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2019;12 (1):34-41. https://doi. org/10.17749/2070-4909.2019.12.1.34-41.
6. Блинов Д. В., Акарачкова Е. С., Орлова А. С., Крюков Е. В., Корабельников Д. И. Новая концепция разработки к линических рекомендаций в России. ФАРМ АКОЭКОНОМИК А. Современна я фармакоэкономика и фармакоэпидемиология. 2019;12 (2):125-144. https://doi.org/10.17749/2070-4909.2019.12.2.125-144.
7. Камилова Д. П., Овчинникова М. М., Абляева Э. Ш., Левиашвили М. М., Стулева Н. С., Бройтман Е. В., Ганихина М. А., Маясина Е. Н., Исхакова Л. Ф., Боярский К. Ю., Овсянникова Е. Н., Барахоева З. Б., Никитин С. В., Бендусов И. А., Фетисова Ю. А., Юдина М. А., Тарарашкина Е. С., Хетагурова Д. Т., Блинов Д. В., Ползиков М. А. Эффективность применения биоаналогового фоллитропина альфа в реальной клинической практике: результаты наблюдательного исследования «ФОЛЛИТРОПИН». Акушерство, Гинекология и Репродукция. 2021;15 (1):5-21. https://doi.org/10.17749/2313-7347/ob. gyn. rep. 2021.212.
8. Бузуверова О. О., Федяева В. К., Сухоруких О. А. Методологические и практические аспекты применения метода RAND/UCLA для разработки клинических рекомендаций и критериев оценки качества медицинской помощи. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2019;12 (4):327-332. https://doi. org/10.17749/2070-4909.2019.12.4.327-332.
9. Омельяновский В. В., Федяева В. К., Мусина Н. З. Концепция многокритериального анализа принятия решений в текущей системе оценки технологий в здравоохранении России. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2018;11 (3):3-7. https://doi.org/10.17749/2070-4909.2018.11.3-003-007.
10. Finn R. S. et al. Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT] //Annals of Oncology. – 2018. – Т. 29. – С. viii17-viii18.
11. Kudo M. Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma. Liver Cancer. 2018 Mar;7 (1):1-19. doi: 10.1159/000487148. PMID: 29662829; PMCID: PMC5892376.
12. Briggs A. et al. Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treat-ment of unresectable hepatocellular carcinoma //British journal of cancer. – 2020. – Т. 122. – №. 12. – С. 1754-1759.
13. Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, O’Beirne J, Fox R, Skowronska A, Palmer D, Yeo W, Mo F, Lai P, Iñarrairaegui M, Chan SL, Sangro B, Miksad R, Tada T, Kumada T, Toyoda H. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015 Feb 20;33 (6):550-8. doi: 10.1200/JCO. 2014.57.9151. Epub 2014 Dec 15. PMID: 25512453; PMCID: PMC4322258.
14. Vogel A., Frenette C., Sung M., Daniele B., Baron A., Chan S. L., Blanc J. F., Tamai T., Ren M., Lim H. J., Palmer D. H., Takami Y., Kudo M. Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma. Liver Cancer. 2021. doi: 10.1159/000516490.
15. Alsina et al. Subsequent anticancer medication: a post hoc analysis from REFLECT; Liver Cancer 2020; 9:93–104; DOI: 10.1159/000504624.
16. Huynh J, Cho MT, Jae-Hoon Kim E, et al. Post hoc analysis in patients (pts) with unresectable hepatocellular carcinoma (uHCC) who progressed to Child-Pugh B (CPB) liver function in the phase III REFLECT study of lenvatinib (LEN). Journal of Clinical Oncology. 39, no. 3_suppl (January 20, 2021) 298-298. DOI: 10.1200/JCO. 2021.39.3_suppl. 298.
17. Sho T. et al. Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria //Hepatology Research. – 2020. – Т. 50. – №. 8. – С. 966-977.
18. Caraceni P, Riggio O, Angeli P, et al. Long-Term albumin administration in decompensated cirrhosis (answer): an open-label randomised trial. Lancet 2018;391:2417–29. HYPERLINK “http://dx.doi.org/10.1016/S0140-6736 (18)30840-7”doi:10.1016/S0140-6736 (18)30840-7.
19. Dang H, Yeo YH, Yasuda S, et al. Cure with Interferon Free DAA is Associated with Increased Survival in Patients with HCV related HCC from both East and West. Hepatology 2020;71:1910-22.
20. Koroki, K., Kanogawa, N., Maruta, S., Ogasawara, S., Iino, Y., Obu, M., Okubo, T., Itokawa, N., Maeda, T., Inoue, M. and Haga, Y., Posttreatment after lenvatinib in patients with advanced hepatocellular carcinoma. Liver Cancer. 2021; pp. 1-12. https://doi. org/10.1159/000515552.
21. Kudo M. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carci-noma: a randomised phase 3 non-inferiority trial //The Lancet. – 2018. – Т. 391. – №. 10126. – С. 1163-1173.
22. Finn R. S. et al. IMbrave150 Investigators et al //Atezolizumab plus bevacizumab in unresectable hepatocellular car-cinoma. N. Engl. J. Med. – 2020. – Т. 382. – №. 20. – С. 1894-1905.
23. Cabibbo G., Celsa C., Enea M., Battaglia S., Rizzo G. E., Grimaudo S., Matranga D., Attanasio M., Bruzzi P., Craxì A., Cammà C. Optimizing sequential systemic therapies for advanced hepatocellular carcinoma: A decision analysis. Cancers. 2020; 12 (8): 21-32.
24. European Association For The Study Of The Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. Journal of hepatology 69.1 (2018): 182-236.
25. Бредер В. В., Косырев В. Ю., Кудашкин Н. Е., Лактионов К. К. Гепатоцеллюлярный рак в Российской Федерации как социальная и медицинская проблема. Медицинский совет. 2016;10: 10-18.
26. Бредер В. В., Балахнин П. В., Виршке Э. Р., Косырев В. Ю., Ледин Е. В., Петкау В. В. Практические рекомендации по лекарственному лечению больных гепатоцеллюлярным раком. DOI: 10.18027/2224-5057-2020-10-3s2-25RUSS-CO, 2020.
27. Клинические рекомендации Рак печени (гепатоцеллюлярный) 2020. МЗ РФ. Интернет ресурс: http://cr. ros-minzdrav. ru/#!/schema/709 Дата обращения: 16.05.2020.
28. Kudo M. et. al., Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child–Pugh A Liver Function: A Proof-Of-Concept Study Cancers 2019, 11, 1084.
29. Llovet J. M. et al. Molecular therapies and precision medicine for hepatocellular carcinoma //Nature reviews Clinical oncology. – 2018. – Т. 15. – №. 10. – С. 599-616.
30. Breder V. V. et al. IMbrave150: Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in a global Ph III study. Journal of Clinical Oncology 2021 39:15_suppl, 4073-4073.
Review
For citations:
Breder V.V., Abdurakhmanov D.T., Petkau V.V., Balakhnin P.V., Volkonsky M.V., Grechukhina K.S., Zafirova M. ., Mikerov I.A., Pokataev I.A., Khasanova A. . Unresectable hepatocellular carcinoma: prospects for drug therapy with lenvatinib. Malignant tumours. 2021;11(3):45-52. (In Russ.) https://doi.org/10.18027/2224-5057-2021-11-3-45-52
Views:
851
Email this article 